Animal evidence expanded · 19 October 2026
A promising result.
Then the next question.
An initial map of peptide research, regulatory distinctions and what animal studies can—and cannot—tell us about future pet care.
Read the model, not just the headline.
Choose the species actually studied. Empty results describe this selected evidence set only. Rats and mice are research species, not dosing templates for dogs, cats, birds, horses, primates or kangaroos.
Study records are loading. The review method and source context remain below.
Dogs and cats first.
The study library includes dog and cat primary-study summaries and negative/safety findings. Read our evidence approach. The six original storefront concepts remain hypothetical; the larger registry does not make them approved products.
Animal-study sources added on 19 October were checked then. Earlier legal/approval material below retains its 15 October review date; this update is not a fresh authorization audit.
Approval is product-specific.
The FDA’s July 2026 agenda concerns BPC-157, KPV, TB-500, MOTS-c, emideltide/DSIP, Semax and Epitalon. GHK-Cu and SS-31 are not on that seven-family agenda. An advisory recommendation is nonbinding; the meeting is not an approval notice. Official vote tallies were not independently verified for this draft. FDA meeting page.
The current text of 21 CFR 216.23, displayed through 14 October 2026, does not list those peptide families in paragraph (a). It also explicitly distinguishes compounding-list inclusion from approval. This section is only one part of the human-compounding framework. Current regulation; FDA pathway explanation.
United States
Animal compounding has its own conditional framework under GFI #256. It does not create approval for a general pet-peptide shop. Product, species, clinical need, prescription and supply circumstances must be assessed. FDA guidance.
Canada
Canadian authorization is separate. Injectables and disease-treatment uses are excluded from the low-risk VHP notification route. Research access does not establish retail clearance. VHP exclusions; Experimental studies.
SS-31 has a genuine approval distinction: Forzinity (elamipretide) received accelerated FDA approval in 2025 for a defined human Barth syndrome indication. That approval does not attach to a generic Pettides cartridge or pet-longevity claim. FDA announcement.
Mexico, state/provincial licensing, advertising, importing, compounding eligibility for every candidate and individual product status require additional review. A “not for human use” label cannot establish veterinary authorization.
The initial candidate registry.
“Not established here” identifies the limits of this review; it is not a definitive negative database search. Approval examples refer to named finished products and indications. No universal list of “FDA-approved research-use peptides” was identified.
| Peptide / product family | Research focus | Regulatory distinction | Evidence extracted |
|---|
The official FDA Green Book, Drugs@FDA and Health Canada’s Drug Product Database are the starting points for a larger approval inventory. A full historical/current peptide-class audit has not been completed.
What a complete review needs next.
This first pass used focused web searches of FDA, eCFR, Health Canada, PubMed and original publications. It is a feasibility scan, not a registered systematic review. Most study records were extracted from abstracts; MOTS-c exposure also uses its indexed figure legend. The 19 October expansion includes selected full-text sections for BPC157 pharmacokinetics and pasireotide, plus an FDA safety appraisal. Search limits and per-source extraction depth are recorded in companion-research.json. Full-method checks, supplementary files and formal risk-of-bias scoring remain outstanding.
- Lock the inventory. Define peptide/polypeptide boundaries, approved versus discontinued products, salts, exact sequences and the two jurisdictions. Record application identifiers, indications, routes and dates.
- Search reproducibly. Use molecule names, synonyms and exact identities with each animal species. Log databases, queries, dates, inclusion rules, duplicates and exclusion reasons.
- Extract full methods. Species, strain, sex, age, health status, sample size, randomization, blinding, comparator, formulation, route, dose, frequency, duration, outcomes, adverse events and funding.
- Retain incompatible units. Concentration, local wound exposure, IU and per-animal doses cannot always become mg/kg. Do not assume body mass, intake, concentration or molecular equivalence.
- Assess bias and replication. Distinguish mechanistic signals from clinical endpoints. Include null/negative results, independent replication and safety/toxicology evidence.
- Set a veterinary research question. A proposed study needs a veterinarian, ethics review, lawful access, justified species/indication, safety monitoring and a prospective protocol. This project supplies none of those approvals.
Animal-study findings are experimental evidence with limitations. They should not be relabelled as anecdotes, proven pet benefits or individual prognosis.
Trace every claim.
Original source entries were checked on 15 October 2026; the dog/cat expansion sources were checked on 19 October 2026. The notes explain what each source contributes. Links may change after that date.